Lymphoma Program

Our Program

Dr. Martha J.
Glenn

Dr. Ahmad
Halwani

Dr. Deborah
Stephens

Dr. John
Sweetenham

Our Physicians

Our Hospital Designations

The lymphoma program provides access to current state-of the-art treatments and clinical trials beyond classical cytotoxic chemotherapy regimens. Treatment options offered today include novel targeted therapies and allogeneic bone marrow transplantation to optimize patient outcomes. 

Diseases treated:

  • Hodgkin’s Lymphoma (HL)
  • Non-Hodgkin’s Lymphoma (NHL-all subtypes)
    • Diffuse Large B-cell Lymphoma (DLBCL)
    • Follicular Lymphoma (FL)
    • Mantle Cell Lymphoma (MCL)
    • Marginal Zone Lymphoma (MZL-all subtypes)
      • Nodal
      • Extranodal 
      • Splenic
      • Mucosa-associated Lymphoid Tissue (MALT)
    • Primary Mediastinal B-cell Lymphoma
    • T-cell lymphoma (TCL-all subtypes)
      • Anaplastic Large Cell
      • Angioimmunoblastic
      • Cutaneous
      • Extranodal NK/Tcell
      • Peripheral T-cell, not otherwise specified
    • Plasmablastic Lymphoma
  • Chronic Lymphocytic Leukemia (CLL)
  • Waldenstrom’s Macroglobulinemia (WM)
  • Large Granular Lymphocytic (LGL) Leukemia
  • Hairy Cell Leukemia (HCL)